Basel, Switzerland, October 9, 2024 – CIS BIOPHARMA, a leading biopharmaceutical innovator, participated in BioTechX Europe, Europe’s premier congress focused on diagnostics, precision medicine, and digital transformation in pharmaceutical development and healthcare. The participation underscores the company’s commitment to advancing pharmaceutical innovation through cutting-edge technologies.
The event provided a strategic platform for the firm to evaluate the latest advancements in Artificial Intelligence (AI) and Large Language Models (LLMs) within the context of biopharmaceutical research and development. Dominik Brücher, the company’s Chief Technology Officer, emphasized their strategic approach: «To optimize AI integration into our workflows, we are forging collaborations with industry-proven experts who have demonstrated success in implementing practical AI solutions.»
Complementing this focus, Christian Geraths, Chief Scientific Officer, articulated the company’s mission-driven approach: «By synergizing AI-derived insights with validated real-world models, we are accelerating the development of innovative therapies. Our goal remains clear: to extend and enhance the lives of cancer patients.»
About CIS BIOPHARMA AG
CIS BIOPHARMA is a privately-owned, Basel-based oncology company developing next-generation immuno-conjugates to address aggressive forms of tumors. The company’s product pipeline includes antibody-drug conjugates, ADCs, and radioligand therapies, RLTs, that selectively target tumor cells. CIS BIOPHARMA is committed to helping cancer patients live longer and better lives.